CARM — Carisma Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.01m
- -$2.77m
- $19.63m
Brief: Carisma Therapeutics Announces Nomination Of First In Vivo Car-M Development Candidate For Hepatocellular Carcinoma Under Collaboration With Moderna
Brief: Carisma Therapeutics Granted FDA Fast Track Designation For CT-0525 For The Treatment Of HER2-Overexpressing Solid Tumors
Brief: Carisma Therapeutics Announces First Patient Dosed In Phase 1 Clinical Trial Of Ct-0525
Carisma Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Carisma Therapeutics Appoints Dr Eugene Kennedy As Chief Medical Officer
Carisma Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Carisma Therapeutics Says First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
Brief: Carisma Therapeutics Says First CT-0525 Patient Expected To Be Treated In First Half Of 2024
Carisma Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Carisma Announces Latest Data From Phase 1 Clinical Trial Of Ct-0508 At 8Th Annual Car-Tcr Summit
Carisma Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Carisma Therapeutics Announces First Patient Dosed In Phase 1 Study Of CT-0508 With KEYTRUDA
Brief: Carisma Therapeutics To Be Added To Russell 2000®, Russell 3000® And Russell Microcap® Indexes
U.S. RESEARCH ROUNDUP-Microsoft, Chevron, Carisma Therapeutics
Carisma Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Carisma Therapeutics Files Prospectus For Resale Of 3.73 Mln Shares Of Common Stock - SEC Filing